A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs CBL-514 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Caliway Biopharmaceuticals Australia
- 05 Dec 2018 Planned number of patients changed from 36 to 40.
- 05 Dec 2018 Planned initiation date changed from 1 Jul 2018 to 11 Dec 2018.
- 05 Dec 2018 Status changed from not yet recruiting to recruiting.